Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 17/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276729 | 0.89 | SLC9A1 (1.00) | SLC9A1CYP1A2CYP3A4CYP2D6MEN1 | |
| SCHEMBL14276811 | 0.88 | SLC9A1 (0.78) | SLC9A1 | |
| SCHEMBL14276736 | 0.88 | SLC9A1 (0.78) | SLC9A1 | |
| SCHEMBL14276748 | 0.86 | SLC9A1 (0.86) | SLC9A1CYP1A2CYP3A4CYP2D6MEN1 | |
| SCHEMBL14276742 | 0.86 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL14276905 | 0.86 | SLC9A1 (0.76) | SLC9A1 | |
| SCHEMBL14276727 | 0.86 | SLC9A1 (1.00) | SLC9A1CYP1A2CYP3A4CYP2D6HSD17B10 | |
| SCHEMBL14276827 | 0.86 | SLC9A1 (0.78) | SLC9A1CYP1A2CYP3A4CYP2D6MEN1 | |
| SCHEMBL14276730 | 0.84 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL14301832 | 0.84 | SLC9A1 (0.84) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |